I doubt very much that your income is high enough to be affected by the new 3.8% Medicare tax on long term capital gains. I think it's great that the Affordable Care Act is referred to as Obamacare so that conservatives can choke every time they say or read it. It's like if Social Security was referred to as Roosevelt Security in the 30's by the Roosevelt haters and that became the name the program was always referred to, to the conservatives disgust.
Could just be a retail blip only fueled by rumor and hope, but maybe the venture capital company that holds the option to buy 3/4's of the company for 12 cents/share, $1.20/share post-reverse split, has some inside knowledge, ( I don't think insider trading rules apply to a penny stock like this) and is starting to accumulate all it can acquire on the open market below their option price.
I doubt any of these companies mentioned in the article have the ability to characterize complicated molecules that MNTA does. MNTA's patented and proven science gives them the ability to repeatedly offer biosimilars as soon patents expire.on the proprietary drugs .MNTA's success with their Lovenex biosimilar will be repeated on a succession of future efforts. Short term without a buyout the stocks has a modest upside with no imminent new products. Possibly the Supreme Court will reverse that rediculous "Safe Harbor" patent infringement decision. Long term this could have a substanial upside.
Cyclacel is using Dacogen as their active control arm in Phase III trials for their candidate to treat AML in seniors. In the article about this it describes this as a potentially "blockbuster drug." How Dacogen performs against their drug should have signifigant consequences for Dacogen's use as a treatment. Hopefully the Dacogen arm of the trial will show signifigantly superior results or at least some additional benefits..